SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David S. who wrote (927)7/10/1997 7:35:00 PM
From: David S.   of 6136
 
to further clarify and be more specific - forgot to quote from Robertson comments..."Also adding fuel to the weakness in AGPH, Agouron announced on Monday some management changes, including that Bob Jackson, a VP of early research, has left the company...shorts took this as negative news". Again, AGPH could have been more specific in their press release. In addition, with the way the press release was worded, not only shorts in the stock, but people who are/were long the stock could interpret the news release as negative - so why say that shorts took this as negative? Re: previous post suggesting Robertson blaming shorts as the cause for the error, the "error" referred to is not the error in putting out a "loose" news release, but in misinterpreting Jackson's position and making a big deal out of it.
Also amusing is Robertson's comment (you'll love this)"Shorts took this as negative news. Has absolutely no significance, in our view. (We don't even know Dr. Jackson)" Perhaps the Robertson analyst should look at AGPH's 1996 annual report. There are 8 officers listed on the rear inside cover. One of them is Jackson, with the title, VP, Research and Development.
hello?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext